MedTrace Logo

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

NCT01522196 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2014-03-04

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).

Conditions

Interventions

DRUG

Varespladib

48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.

OTHER

Placebo (Normal Saline)

48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.

Sponsors & Collaborators

  • Anthera Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01522196 on ClinicalTrials.gov